My research interests include several methods of identifying novel biomarkers and building predictive models of outcomes in radiation oncology using bioinformatics and machine learning techniques. Despite many efforts to identify early diagnostic biomarkers in cancer, the lack of efficient computational approaches has been a major obstacle. In addition, building robust models is of vital importance to the accurate prediction of outcomes in cancer. Taken together, my research strives to bring cutting-edge computational and statistical methods, based on bioinformatics and machine learning techniques, to achieve these goals.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jung Hun Oh discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.